Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2013

View Archived Issues

Subcutaneous grass pollen monomeric carbamylated allergoid tested in allergic rhinoconjunctivitis

Changes in FXIII observed in patients with myocardial infarction

Matrix metalloproteinase-10 levels increased in patients with peripheral artery disease

New ACC-beta inhibitors synthesized by Boehringer Ingelheim

Ironwood Pharmaceuticals prepares new sGC activators

BioDiem's liver disease vaccine program achieves proof of principle

Roche launches Elecsys ProGRP test to diagnose small cell lung cancer

Medigen Biotechnology provides update on phase III PATRON trial

BioCryst completes phase I trial of BCX-4161

Xoma provides update on development program for gevokizumab

Bio-Path begins development of liposomal GRB2 for two breast cancer indications

Merrimack begins patient enrollment in phase II trial in advanced gastroesophageal cancers

MBio Diagnostics receives NIH grant to continue development of POC HIV diagnostic device

Researchers disclose new agents for sickle cell disease and other disorders

Agios Pharmaceuticals divulges new IDH2 inhibitors for cancer

Spinifex Pharmaceuticals synthesizes novel AT2 receptor antagonists

Alzheimer's disease vaccine vanutide evaluated in Japanese patients in phase II study

Janssen R&D patents novel agents for HBV infection

AB Science receives funding to develop therapy for Alzheimer's disease

Galapagos earns milestone in osteoarthritis alliance with Servier

New sodium channel blockers presented by Pfizer

Phase II data reported for BMS-927711 in migraine

Prana completes phase II trial of lead candidate in Huntington's disease

Atterocor commences first-in-human trial of ATR-101 in advanced adrenocortical carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...